ABEONA THERAPEUTICS INC.: Kaufman Daniel Louis amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Kaufman Daniel Louis amended his Schedule 13G stake filing for Abeona Therapeutics Inc., disclosing the change to the SEC under accession number 0001099910-26-000305. The filing updates his previously reported beneficial ownership position in the clinical-stage gene and cell therapy company. Schedule 13G amendments are typically filed by passive investors and signal shifts in large holders' stakes. The exact revised share count and percentage were not specified in the filing notice. Investors will watch for further 13G or 13D filings to gauge whether Kaufman's position continues to change.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Abeona Therapeutics Inc., Kaufman Daniel Louis